SEC Info - Actinium Pharmaceuticals, Inc. - ‘10-Q’ for 9/30/19

SEC Info℠

Home

Help

Please Sign In

Actinium Pharmaceuticals, Inc. – ‘10-Q’ for 9/30/19 – ‘EX-101.CAL’

On: Tuesday, 11/12/19, at 4:32pm ET · For: 9/30/19 · Accession #: 1213900-19-22937 · File #: 1-36374

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/12/19  Actinium Pharmaceuticals, Inc.    10-Q        9/30/19   40:2.3M                                   Edgar Agents LLC/FA

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    346K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     19K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     19K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     15K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     15K 
25: R1          Document and Entity Information                     HTML     48K 
38: R2          Consolidated Balance Sheets (Unaudited)             HTML     87K 
33: R3          Consolidated Balance Sheets (Unaudited)             HTML     36K 
                (Parenthetical)                                                  
14: R4          Consolidated Statements of Operations (Unaudited)   HTML     50K 
24: R5          Consolidated Statement of Changes in Stockholders'  HTML     64K 
                Equity                                                           
37: R6          Consolidated Statements of Cash Flows (Unaudited)   HTML     74K 
32: R7          Description of Business and Summary of Significant  HTML     50K 
                Accounting Policies                                              
15: R8          Commitments and Contingencies                       HTML     26K 
23: R9          Leases                                              HTML     34K 
29: R10         Equity                                              HTML     38K 
35: R11         Description of Business and Summary of Significant  HTML     84K 
                Accounting Policies (Policies)                                   
21: R12         Description of Business and Summary of Significant  HTML     25K 
                Accounting Policies (Tables)                                     
12: R13         Leases (Tables)                                     HTML     36K 
30: R14         Equity (Tables)                                     HTML     31K 
36: R15         Description of Business and Summary of Significant  HTML     27K 
                Accounting Policies (Details)                                    
22: R16         Description of Business and Summary of Significant  HTML     22K 
                Accounting Policies (Details 1)                                  
13: R17         Description of Business and Summary of Significant  HTML     27K 
                Accounting Policies (Details Textual)                            
31: R18         Commitments and Contingencies (Details Textual)     HTML     36K 
34: R19         Leases (Details)                                    HTML     25K 
19: R20         Leases (Details 1)                                  HTML     27K 
16: R21         Leases (Details 2)                                  HTML     18K 
27: R22         Leases (Details 3)                                  HTML     18K 
40: R23         Leases (Details 4)                                  HTML     31K 
20: R24         Leases (Details Textual)                            HTML     27K 
17: R25         Equity (Details)                                    HTML     70K 
28: R26         Equity (Details Textual)                            HTML     87K 
39: XML         IDEA XML File -- Filing Summary                      XML     64K 
18: EXCEL       IDEA Workbook of Financial Reports                  XLSX     34K 
 6: EX-101.INS  XBRL Instance -- atnm-20190930                       XML    524K 
 8: EX-101.CAL  XBRL Calculations -- atnm-20190930_cal               XML     95K 
 9: EX-101.DEF  XBRL Definitions -- atnm-20190930_def                XML    274K 
10: EX-101.LAB  XBRL Labels -- atnm-20190930_lab                     XML    671K 
11: EX-101.PRE  XBRL Presentations -- atnm-20190930_pre              XML    444K 
 7: EX-101.SCH  XBRL Schema -- atnm-20190930                         XSD    111K 
26: ZIP         XBRL Zipped Folder -- 0001213900-19-022937-xbrl      Zip     74K

‘EX-101.CAL’ — XBRL Calculations — atnm-20190930_cal

This Exhibit is an XBRL XML File.

<?xml version="1.0" standalone="no" encoding="windows-1252"?>

<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" xlink:href="atnm-20190930.xsd#DocumentAndEntityInformation" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/BalanceSheets" xlink:href="atnm-20190930.xsd#BalanceSheets" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:href="atnm-20190930.xsd#BalanceSheetsParenthetical" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/StatementsOfOperations" xlink:href="atnm-20190930.xsd#StatementsOfOperations" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:href="atnm-20190930.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/StatementsOfCashFlows" xlink:href="atnm-20190930.xsd#StatementsOfCashFlows" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:href="atnm-20190930.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="atnm-20190930.xsd#CommitmentsAndContingencies" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/Leases" xlink:href="atnm-20190930.xsd#Leases" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/Equity" xlink:href="atnm-20190930.xsd#Equity" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="atnm-20190930.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="atnm-20190930.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesTables" xlink:href="atnm-20190930.xsd#LeasesTables" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityTables" xlink:href="atnm-20190930.xsd#EquityTables" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="atnm-20190930.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:href="atnm-20190930.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="atnm-20190930.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="atnm-20190930.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails" xlink:href="atnm-20190930.xsd#LeasesDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails1" xlink:href="atnm-20190930.xsd#LeasesDetails1" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails2" xlink:href="atnm-20190930.xsd#LeasesDetails2" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails3" xlink:href="atnm-20190930.xsd#LeasesDetails3" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails4" xlink:href="atnm-20190930.xsd#LeasesDetails4" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetailsTextual" xlink:href="atnm-20190930.xsd#LeasesDetailsTextual" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails" xlink:href="atnm-20190930.xsd#EquityDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual" xlink:href="atnm-20190930.xsd#EquityDetailsTextual" xlink:type="simple"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets (Unaudited)">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash"/>

<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset"/>

<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset"/>

<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent"/>

<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="atnm-20190930.xsd#atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:label="loc_atnmLongtermOperatingLeaseObligationsNoncurrent"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_atnmLongtermOperatingLeaseObligationsNoncurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="atnm-20190930.xsd#atnm_LongtermFinanceLeaseObligationsNoncurrent" xlink:label="loc_atnmLongtermFinanceLeaseObligationsNoncurrent"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_atnmLongtermFinanceLeaseObligationsNoncurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit"/>

<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations (Unaudited)">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="atnm-20190930.xsd#atnm_ProvisionOfDeemedDividendForWarrantDownroundProtection" xlink:label="loc_atnmProvisionOfDeemedDividendForWarrantDownroundProtection"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_atnmProvisionOfDeemedDividendForWarrantDownroundProtection" xlink:type="arc" weight="-1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statement of Changes in Stockholders' Equity"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>

<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization"/>

<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="atnm-20190930.xsd#atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_atnmIncreaseDecreaseInOperatingLeaseLiabilities"/>

<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_atnmIncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireFinanceReceivables" xlink:label="loc_us-gaapPaymentsToAcquireFinanceReceivables"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsToAcquireFinanceReceivables" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="atnm-20190930.xsd#atnm_ProceedsFromIssuanceOfCommonStockAndWarrantNet" xlink:label="loc_atnmProceedsFromIssuanceOfCommonStockAndWarrantNet"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_atnmProceedsFromIssuanceOfCommonStockAndWarrantNet" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises"/>

<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - Description of Business and Summary of Significant Accounting Policies"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="00000008 - Disclosure - Commitments and Contingencies"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Leases" xlink:title="00000009 - Disclosure - Leases"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Equity" xlink:title="00000010 - Disclosure - Equity"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000011 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000012 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesTables" xlink:title="00000013 - Disclosure - Leases (Tables)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityTables" xlink:title="00000014 - Disclosure - Equity (Tables)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000015 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:title="00000016 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details 1)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="00000017 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details Textual)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:title="00000018 - Disclosure - Commitments and Contingencies (Details Textual)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails" xlink:title="00000019 - Disclosure - Leases (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails1" xlink:title="00000020 - Disclosure - Leases (Details 1)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails2" xlink:title="00000021 - Disclosure - Leases (Details 2)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails3" xlink:title="00000022 - Disclosure - Leases (Details 3)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails4" xlink:title="00000023 - Disclosure - Leases (Details 4)">

<link:loc xlink:type="locator" xlink:href="atnm-20190930.xsd#atnm_LeaseLiabilityPaymentsDue" xlink:label="loc_atnmLeaseLiabilityPaymentsDue"/>

<link:loc xlink:type="locator" xlink:href="atnm-20190930.xsd#atnm_MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_atnmMaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_atnmLeaseLiabilityPaymentsDue" xlink:to="loc_atnmMaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="atnm-20190930.xsd#atnm_MaturitiesLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearTwo"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_atnmLeaseLiabilityPaymentsDue" xlink:to="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="atnm-20190930.xsd#atnm_MaturitiesLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearThree"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_atnmLeaseLiabilityPaymentsDue" xlink:to="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="atnm-20190930.xsd#atnm_MaturitiesLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearFour"/>

<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_atnmLeaseLiabilityPaymentsDue" xlink:to="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="atnm-20190930.xsd#atnm_MaturitiesLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearFive"/>

<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_atnmLeaseLiabilityPaymentsDue" xlink:to="loc_atnmMaturitiesLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="atnm-20190930.xsd#atnm_MaturitiesOfLeaseLiabilities" xlink:label="loc_atnmMaturitiesOfLeaseLiabilities"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_atnmMaturitiesOfLeaseLiabilities" xlink:to="loc_atnmLeaseLiabilityPaymentsDue" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="atnm-20190930.xsd#atnm_PaymentWithImputedInterestPremium" xlink:label="loc_atnmPaymentWithImputedInterestPremium"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_atnmMaturitiesOfLeaseLiabilities" xlink:to="loc_atnmPaymentWithImputedInterestPremium" xlink:type="arc" weight="-1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetailsTextual" xlink:title="00000024 - Disclosure - Leases (Details Textual)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails" xlink:title="00000025 - Disclosure - Equity (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetailsTextual" xlink:title="00000026 - Disclosure - Equity (Details Textual)"/>

</link:linkbase>

↑Top

Filing Submission 0001213900-19-022937 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Actinium Pharmaceuticals, Inc. – ‘10-Q’ for 9/30/19 – ‘EX-101.CAL’

On: Tuesday, 11/12/19, at 4:32pm ET · For: 9/30/19 · Accession #: 1213900-19-22937 · File #: 1-36374

Previous ‘10-Q’: ‘10-Q’ on 8/9/19 for 6/30/19 · Next: ‘10-Q’ on 6/29/20 for 3/31/20 · Latest: ‘10-Q’ on 4/26/24 for 3/31/24

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34Filing Table of Contents

‘EX-101.CAL’ — XBRL Calculations — atnm-20190930_cal

This Exhibit is an XBRL XML File.

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents